Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).
Sagar Lonial, Ho‐Young Yhim, Vanesa Caruso, Jae-Cheol Jo, Sung‐Hoon Jung, Youngil Koh, Peter Barth, Samineh Deheshi, Eleftheria Kalaitzaki, Brandon E. Kremer, Julia Boyle, Nicola Jackson, Wei Sun, Fernando Carreno, Pralay Mukhopadhyay, Joanna Opalińska, Meletios A Dimopoulos (2025). Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps7567.
